Bio-Path Holdings to Announce Full Year 2020 Financial Results on March 10, 2021
Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company
leveraging its proprietary DNAbilize® antisense RNAi nanoparticle
technology to develop a portfolio of targeted nucleic acid cancer
drugs, today announced that it will host a live conference call and
audio webcast on Wednesday, March 10, 2021 at 8:30 a.m. ET to
report financial results for the year ended December 31, 2020 and
to provide a business overview.
To access the live conference call, please call (844) 815-4963
(domestic) or (210) 229-8838 (international) at least five minutes
prior to the start time and refer to conference ID 6296959. A live
audio webcast of the call will also be available on the
Presentations section of the Company’s website,
www.biopathholdings.com. An archived webcast will be available on
the Bio-Path website approximately two hours after the event.
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company developing DNAbilize®, a
novel technology that has yielded a pipeline of RNAi nanoparticle
drugs that can be administered with a simple intravenous infusion.
Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting
the Grb2 protein), is in a Phase 2 study for blood cancers and
prexigebersen-A, a drug product modification of prexigebersen, is
under consideration by the FDA to commence Phase 1 studies in solid
tumors. This is followed by BP1002, targeting the Bcl-2 protein,
where it is being evaluated in lymphoma clinical studies. For more
information, please visit the Company's website at
Will O’ConnorStern Investor Relations
Doug Morris Investor Relations Bio-Path Holdings, Inc.